From Verify.Wiki
Jump to: navigation, search

Biocon Limited (BSE: 532523) is an Indian biopharmaceutical company based in Bangalore, India.[2] The Company manufactures generic active pharmaceutical ingredients (APIs) that are sold in over 120 countries across the globe, including the developed markets of the United States and Europe. It also manufactures novel biologics, as well as, biosimilar insulins and antibodies, which are sold in India as branded formulations. Biocon's biosimilar products are also sold in both bulk and formulation forms in several emerging markets. In research services, Syngene International Limited (Syngene), a publicly listed subsidiary of Biocon, is engaged in the business of integrated end-to-end drug discovery and development services.

Some of Biocon’s key brands in India include INSUGEN® (rh-insulin), BASALOG® (Glargine), BIOMAb EGFR™ (Nimotuzumab), BLISTO® (Glimepiride + Metformin), CANMAb™ (Trastuzumab), Evertor® (Everolimus), TACROGRAF™ (Tacrolimus) and ALZUMAb™(Itolizumab), which are claimed to be considerably less expensive than other leading brands.[2] Two of its novel programs on the verge of proof-of-concept stage are IN-105, which is the only oral insulin in the world to be in long duration clinical trials, and T1h, a novel humanised monoclonal antibody (MAb), the only first-in-class novel MAb being tested in India for rheumatoid arthritis and psoriasis.[2][3] Biocon Ltd. is one of the largest Indian biopharmaceutical company which offer its services in more than 120 countries. Established in 1978 by Ms Kiran Mazumdar-Shaw, With more than 6,700 employees, Biocon is committed to reduce therapy costs of chronic diseases like diabetes, cancer and autoimmune diseases. [1] Biocon’s key innovations include world’s first Pichia-based recombinant human Insulin, INSUGEN®, insulin analogue Glargine, BASALOG®, and India’s first indigenously produced monoclonal antibody, BioMAb EGFR® , for head & neck cancer. [2]

QuickUpload1032 20170611215857.png
Type Public
Industry Biotechnology
Founded 1978
Headquarters Bangalore, Karnataka
Number of employees 5,001-10,000


To enhance global healthcare through innovative and affordable biopharmaceuticals for patients, partners and healthcare systems across the globe


To be an integrated biotechnology enterprise of global distinction.

Essential to this mission is excellence in:

- Intellectual asset creation through discovery, research and development

- State-of-the-art manufacturing capabilities

- Internationally benchmarked quality and regulatory systems

- New medical insight through disease specific

 clinical research

- Customer relationship through outstanding products

 and services

- Human resource development through training,

 mentoring and empowering

- Management of research and business partnerships


- Integrity and Ethical Behaviour

- Performance driven work culture

- Value Creation through Innovation & Differentiation

- Quality through Compliance & Best Practices

- Collaboration, Team Work & Mutual Respect

Cite error: Closing </ref> missing for <ref> tag

Verification history